Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Described herein is a method for treating an autoimmune disease in a patient including administering to the patient in need thereof, a pharmaceutically effective amount of an epigenetic enzyme inhibitor.

Described herein is a method for treating an autoimmune disease in a patient including administering to the patient in need thereof, a pharmaceutically effective amount of an epigenetic enzyme inhibitor.

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.

Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.